NCT01887353

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful External Electrical Cardioversion

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Intermountain Health Care, Inc. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.

Conditions

• Atrial Fibrillation
• Heart Failure

Interventions

Type	Name	Description
DRUG	Ranolazine	Patients will take ranolazine 1000 mg tablets twice daily
DRUG	Placebo	Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.

Timeline

• Start date: 2013-06-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2013-06-26
• Last updated: 2015-07-20
• Results posted: 2015-07-20

Locations

1 site across 1 country: United States